Mahony Susan sold $145K of AXSM
Mahony Susan sold 600 shares of Axsome Therapeutics, Inc. (AXSM) at an average of $241.70 ($237.21–$246.18, $0.15M total) across 2 trades over 2026-06-09 to 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms open-market selling of 600 shares at $237.21–$246.18, but the presence of a pre-arranged 10b5-1 plan generally lowers the informational content versus discretionary sales.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company catalysts.
What to watch
The article provides only the sale details; it does not state whether other insiders bought, whether the company had concurrent catalysts, or whether the director’s remaining holdings change materially.
Background
This is a primary-source SEC Form 4 insider transaction disclosure for Axsome Therapeutics director Susan Mahony.
Ticker impact
Director Susan Mahony sold $145,017 of Axsome Therapeutics shares via two open-market trades under a pre-arranged 10b5-1 plan (Form 4).
Likely minimal near-term impact; any effect should be short-lived unless accompanied by other company-specific news.
The filing is an insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretability as a discretionary bearish bet.
Market effects
No clear sector read-through; this is company-specific insider liquidity rather than regulatory/clinical/product news.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still coincide with internal views on valuation or liquidity needs; traders may watch for follow-on sales patterns.
Key entities
- issuerAxsome Therapeutics, Inc.
US-listed company whose director insider sale is disclosed on SEC Form 4.
- insiderSusan Mahony
Director who sold 600 shares under a pre-arranged 10b5-1 plan.
